Lytix Biopharma ASA: Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumors

Oslo, Norway, November 5, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that it has been awarded NOK 12 million by the Research Council of Norway under the Innovation Project for the Industrial Sector (IPN) scheme. The grant will fund the development of new formulations of Lytix's oncolytic molecules designed for intratumoral injections.

IPN grants are awarded through a competitive national call in which applications are assessed by independent experts on their degree of innovation, potential impact and the applicant's ability to execute.

"We are very grateful to the Research Council of Norway for this grant. Being selected to receive this grant is a strong recognition of the scientific quality of our platform and of the work we do together with our research partners", said Øystein Rekdal, CEO of Lytix Biopharma.

About Lytix Biopharma ASA

Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to achieve durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules with potential across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker symbol LYTIX.

For further information, please contact:

Gjest Breistein, CFO

E-mail: gjest.breistein@lytixbiopharma.com

For more information, visit www.lytixbiopharma.com.